Paulson & CO. Inc. boosted its stake in shares of Kamada Ltd. (NASDAQ:KMDA) by 8.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 790,800 shares of the biotechnology company’s stock after buying an additional 60,000 shares during the period. Paulson & CO. Inc. owned approximately 2.17% of Kamada worth $4,745,000 as of its most recent filing with the SEC.
Other hedge funds also recently made changes to their positions in the company. Edmond DE Rothschild Holding S.A. raised its holdings in Kamada by 17.8% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 38,200 shares of the biotechnology company’s stock worth $266,000 after buying an additional 5,772 shares during the period. Navellier & Associates Inc acquired a new stake in Kamada during the 2nd quarter worth approximately $303,000. Renaissance Technologies LLC raised its holdings in Kamada by 16.7% during the 1st quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock worth $1,801,000 after buying an additional 37,800 shares during the period. Nexthera Capital LP acquired a new stake in shares of Kamada in the second quarter valued at approximately $1,805,000. Finally, Vanguard Group Inc. raised its holdings in shares of Kamada by 6.5% in the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after purchasing an additional 28,382 shares during the last quarter. Hedge funds and other institutional investors own 7.28% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/10/27/paulson-co-inc-purchases-60000-shares-of-kamada-ltd-kmda.html.
Kamada Ltd. (NASDAQ KMDA) traded up 0.40% during trading on Friday, reaching $5.07. 8,964 shares of the company’s stock were exchanged. The firm’s market cap is $189.62 million. The firm’s 50-day moving average price is $4.77 and its 200-day moving average price is $5.81. Kamada Ltd. has a 12 month low of $3.75 and a 12 month high of $8.61.
Kamada (NASDAQ:KMDA) last issued its earnings results on Tuesday, August 1st. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.12 by $0.01. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The business had revenue of $32.55 million during the quarter, compared to the consensus estimate of $33.30 million. During the same quarter last year, the company earned ($0.04) EPS. The firm’s revenue was up 70.7% compared to the same quarter last year. On average, equities research analysts anticipate that Kamada Ltd. will post $0.09 EPS for the current year.
A number of analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Kamada from a “sell” rating to a “hold” rating in a report on Wednesday. TheStreet downgraded shares of Kamada from a “c-” rating to a “d+” rating in a report on Tuesday, August 1st. Jefferies Group LLC reiterated a “buy” rating and issued a $7.00 price objective (down from $9.00) on shares of Kamada in a report on Wednesday, August 2nd. Finally, ValuEngine cut shares of Kamada from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. Kamada currently has a consensus rating of “Hold” and an average price target of $8.50.
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.